1-2

Sidmak focuses towards enhanced safety and comfort for the human lives through committed perfection and to service the domestic as well as global customers with the products of international standards.
Sidmak aims to become leading player in Novel Drug Delivery System and stretch its core competency to achieve a competitive and sustainable advantage in the global pharmaceutical industry.

Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with eight molecules in various stages of clinical development. The company has a significant presence in branded generics markets across emerging economies including India. Its subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business. The subsidiary also markets APIs to regulated and semi-regulated countries.

Mangalam Drugs & Organics Ltd. - Commenced its business in 1977 of manufacturing of chemicals such as perfumery, organic/inorganic chemicals, disperse dye intermediates, bulk drugs and bulk drugs intermediates at VAPI-Gujarat State.

Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia.

Arch Pharmalabs has gained recognition as a world-class provider of small molecule process chemistry, custom synthesis services and full life-cycle API and drug intermediates manufacture for the global pharmaceutical industry. Generating revenues of USD 200 million, our India-based offering is supported by 2,400 customer-centric Archers, eleven certified facilities (including cGMP-compliant, US FDA- and EDQM-approved sites) and two state-of-the-art Process Technology centres.

Arch Pharmalabs has gained recognition as a world-class provider of small molecule process chemistry, custom synthesis services and full life-cycle API and drug intermediates manufacture for the global pharmaceutical industry. Generating revenues of USD 200 million, our India-based offering is supported by 2,400 customer-centric Archers, eleven certified facilities (including cGMP-compliant, US FDA- and EDQM-approved sites) and two state-of-the-art Process Technology centres.

Wockhardt is a global, pharmaceutical and biotechnology company that has grown by leveraging two powerful trends impacting the world of medicine - globalisation and biotechnology.

Sahajanand Medical Technologies is a leading developer and manufacturer of minimally invasive coronary stent systems, with one of the broadest product portfolio in the industry. We committed to the welfare of all patients around the world; we shall provide best evidence based products to fight cardiovascular disease. Sahajanand Medical Technologies has a strong international presence and we are proud to be a first company to secure CE mark for biodegradable polymer based Drug Eluting Stents.